Tumor News and Research

RSS

Inhibition of miR-24-3p may serve as potential treatment target for mesothelioma

Inhibition of miR-24-3p reduced growth of cancer cells and was found to regulate proteins as a potential treatment target for Mesothelioma.

25 Aug 2018

Researchers develop new system for effective cancer diagnosis and treatment

A research group consisting of scientists from NUST MISIS, the Technical University of Munich, Helmholtz Zentrum München, the University of Duisburg-Essen, and the University of Oldenburg has developed a system that allows doctors to both improve the accuracy of diagnosing malignant cells and to provide additional opportunities for cancer treatment.

24 Aug 2018

New treatment destroys part of tumor and attacks persistent surviving cancer cells

Scientists at the VIB-UGent Center for Medical Biotechnology have taken important steps forward in the development of a cancer-targeting immunotherapy.

24 Aug 2018

Researchers work to create humanized mouse model to test immunotherapies

If a new anti-cancer drug shows promise in a Petri dish, often the next step is to test the drug's effect in mice. This system tends to work well with drugs that directly target cancer, but breaks down with immunotherapies.

24 Aug 2018

Comprehensive analysis reveals weaknesses to target in common pediatric solid tumor

St. Jude Children's Research Hospital investigators have completed the most comprehensive analysis yet of a common pediatric solid tumor, identifying weaknesses to target and a promising precision medicine that is now in clinical trials.

23 Aug 2018

'Plastic antibodies' effectively target and eliminate tumor cells

A joint research team from Russia and the U.K. has demonstrated the possibility of developing a new type of anti-neoplastic drugs based on nanoMIPs, or "plastic antibodies." NanoMIPs are synthetic polymers that can function as antibodies, selectively binding to target proteins on the surface of cancer cells.

23 Aug 2018

GW researchers to develop model for studying role of COMPASS protein in pancreatic cancer

Pancreatic cancer is the fourth most common cause of cancer related deaths in the United States with a five-year survival rate of less than 10 percent. Although it is defined by a small number of genetic alterations, efforts to pharmacologically target specific pathways have been unsuccessful.

23 Aug 2018

Bluebird bio collaborates with Gritstone Oncology to develop novel cancer cell therapies

Bluebird bio, Inc. and Gritstone Oncology, Inc. today announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.

23 Aug 2018

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commission has granted a marketing authorization for the oral receptor tyrosine kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.

23 Aug 2018

Immunotherapy combination shrinks melanoma that has spread to the brain

Combination immunotherapy shrank melanoma that has spread to the brain in more than half of the patients in a clinical trial reported in the New England Journal of Medicine led by an investigator at The University of Texas MD Anderson Cancer Center.

23 Aug 2018

Surgically-removed tumor specimens can help quickly evaluate cancer drug efficacy

Genetic differences can affect the susceptibility of cancer cells to different drugs. In a new Molecular Oncology study, investigators show that surgically-removed breast and prostate tumor specimens can be used to rapidly screen different drugs to see which ones most effectively target an individual's cancer cells.

22 Aug 2018

Radiation therapy impairs new memory formation in pediatric brain tumor patients

Young people who received radiation therapy for the most common pediatric brain tumor struggle to create new memories about specific events, according to a study of children and adolescents published in JNeurosci. Their ability to recall events prior to treatment, however, remains intact.

From Society for Neuroscience 22 Aug 2018

FDA approves Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma

Agilent Technologies Inc. today announced that the U.S. Food and Drug Administration has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma.

22 Aug 2018

Gene therapy with telomerase does not increase cancer risk, study shows

Negative results and findings in science are perhaps less newsworthy, but they are no less important. Particularly when, as in this case, they demonstrate that a possible new therapeutic pathway against idiopathic pulmonary fibrosis and other diseases associated to short telomeres is in fact safe.

21 Aug 2018

Pediatric brain tumor patients who undergo radiation less likely to recall recently experienced events

Children with certain types of brain tumors who undergo radiation treatment are less likely to recall the specifics of events they experienced after radiation than to remember pre-treatment happenings, according to a Baylor University study comparing them to children with healthy brains.

21 Aug 2018

Scientists find two molecules that may combat cancer and chronic infections

To fight viral infections, your immune system calls on CD8 T cells to kill the infected cells. The CD8 T cells can also be used in immunotherapy approaches to kill cancer cells, including the CAR T cell therapy currently attracting broad public attention.

21 Aug 2018

New study describes effect of radiation exposure on hormone deficiency in children

In a new study, University of Cincinnati researchers, in collaboration with Massachusetts General Hospital, have detailed the effect of radiation exposure on the development of hormone deficiency in pediatric and young adult patients treated for brain tumors.

21 Aug 2018

Researchers develop gene expression predictor for immunotherapy response in melanoma

In a new study, researchers developed a gene expression predictor that can indicate whether melanoma in a specific patient is likely to respond to treatment with immune checkpoint inhibitors, a novel type of immunotherapy.

20 Aug 2018

Researchers find STAT3 as therapeutic target for chronic active EBV infection

Tokyo Medical and Dental University study shows that ruxolitinib-induced inhibition of STAT3 activity blocks survival and reduces pro-inflammatory cytokine production in Epstein-Barr virus (EBV)-infected clonally proliferating T- or NK-cells in Chronic active Epstein-Barr virus infection.

20 Aug 2018

Aravive Biologics gains Fast Track Designation for AVB-S6-500 from U.S. FDA

Aravive Biologics, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track Designation to AVB-S6-500 as a potential treatment for platinum-resistant recurrent ovarian cancer.

20 Aug 2018

Tumor News and Research

Inhibition of miR-24-3p may serve as potential treatment target for mesothelioma

Researchers develop new system for effective cancer diagnosis and treatment

New treatment destroys part of tumor and attacks persistent surviving cancer cells

Researchers work to create humanized mouse model to test immunotherapies

Comprehensive analysis reveals weaknesses to target in common pediatric solid tumor

'Plastic antibodies' effectively target and eliminate tumor cells

GW researchers to develop model for studying role of COMPASS protein in pancreatic cancer

Bluebird bio collaborates with Gritstone Oncology to develop novel cancer cell therapies

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Immunotherapy combination shrinks melanoma that has spread to the brain

Surgically-removed tumor specimens can help quickly evaluate cancer drug efficacy

Radiation therapy impairs new memory formation in pediatric brain tumor patients

FDA approves Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma

Gene therapy with telomerase does not increase cancer risk, study shows

Pediatric brain tumor patients who undergo radiation less likely to recall recently experienced events

Scientists find two molecules that may combat cancer and chronic infections

New study describes effect of radiation exposure on hormone deficiency in children

Researchers develop gene expression predictor for immunotherapy response in melanoma

Researchers find STAT3 as therapeutic target for chronic active EBV infection

Aravive Biologics gains Fast Track Designation for AVB-S6-500 from U.S. FDA

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News